WO2004009083A1 - Antitumor compound and therapeutic uses thereof - Google Patents
Antitumor compound and therapeutic uses thereof Download PDFInfo
- Publication number
- WO2004009083A1 WO2004009083A1 PCT/EP2003/007963 EP0307963W WO2004009083A1 WO 2004009083 A1 WO2004009083 A1 WO 2004009083A1 EP 0307963 W EP0307963 W EP 0307963W WO 2004009083 A1 WO2004009083 A1 WO 2004009083A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- use according
- tumors
- ret
- treatment
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention regards the use of the compound (E)-l,3-dihydro- 5,6-dimethoxy-3-[(4-hydroxyphenyl)methylene]-2H-indol-2-one in the treatment of tumors involving Met, PDGF-R, FGF-RI, FGF-R3 and Kit tyrosine kinases, or Ret oncoproteins.
- Met Met, PDGF-R, FGF-RI, FGF-R3 and Kit tyrosine kinases, or Ret oncoproteins.
- RET PTC oncogenes are involved in the transforming processes of human papillary thyroid tumors and originate from the rearrangement of the tyrosine kinase domain of proto-RET with different donor genes.
- the products of such gene rearrangements show ligand-independent tyrosine-kinase activity and are localized in the cytoplasm.
- Ret/ptcl is the product of the RET/PTCl oncogene, which originates from the rearrangement of the proto-RET tyrosine kinase domain with the H4/D10S170 gene.
- Cpd 1 l,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl)methylene]-2H-indol-2-one derivative
- Cpd 1 has now been found to effectively inhibit tyrosine kinases, other than Ret/ptcl, that play a central role in tumor onset, progression and spreading to distant organs. Specifically, Cpd 1 has been shown to completely inhibit the autophosphorylation of Ret/MEN2A (mutations C634R and C634 ), Ret/MEN2B (mutM918T), Met, PDGF-R, FGF-RI, FGF-R3 and Kit (c-Kit and mut ⁇ 559) tyrosine kinases, to reduce their expression (down- regulation) and to revert the phenotype of cells thereby transformed.
- Object of the invention is therefore the use of the compound (E)-l,3- dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl)methylene]-2H-indol-2-one, or of its salts with pharmaceutically acceptable bases, for the treatment of tumors involving at least one of Met, PDGF-R, FGF-RI, FGF-R3 and Kit tyrosine kinases, or involving at least one oncoprotein of the Ret family, including Ret receptors carrying MEN2-associated mutations, in the initial stages of cell transformation or in the following stages of tumor proliferation and dissemination.
- the invention also concerns the use of any stereoisomer or tautomeric form of Cpd.1.
- MTC medullary thyroid carcinomas
- MEN2- associated diseases including MTC, pheochromocytoma, parathyroid hyperplasia, and enteric ganglioneuromas.
- Met inhibition is useful to antagonize the invasive/metastatic phenotype of tumors of epithelial origin. With respect to Met- activating alterations, Cpd 1 may also have a specific indication in the therapy of kidney tumors. Kit inhibition is useful in the treatment of gastrointestinal stromal tumors, small cell lung carcinomas, seminomas and hematological malignancies such as mastocytosis and acute myelogenous leukemia.
- Cpd 1 can be used for the treatment of melanomas and gliomas expressing high levels of FGF-RI and of the respective bFGF ligand eventually involved in autocrine loops. Since this receptor has an important role in angiogenic processes, its inhibition by means of Cpd 1 is useful for the control of tumor vascularization.
- FGF-R3 inhibition is useful in the treatment of multiple myeloma, bladder and cervix carcinomas.
- RPI-1 and its salts can be formulated with pharmaceutically acceptable vehicles and excipients.
- the phenol function of Cpd 1 can be salif ⁇ ed by treatment with suitable organic or inorganic bases.
- the pharmaceutical compositions can be administered by the oral, parenteral, sublingual or transdermic routes, preferably in the form of tablets, capsules, granules, powders, syrups, solutions, suspensions, suppositories, controlled release forms.
- the compositions can be prepared with conventional techniques, using ingredients known in the art.
- the quantity of active principle can be varied depending on the severity of the disease, age of the patient, type and route of administration, but in general an amount of 0.1 to 1000 mg/Kg, preferably from 5 to 300 mg/Kg, more preferably from 20 to 200 mg/Kg, in single or multiple doses one or more times a day, is used.
- Ret oncoproteins carrying aminoacid substitutions which cause constitutive tyrosine kinase activity are involved in sporadic MTC and in the inherited type 2 Multiple Endocrine Neoplasia syndromes (MEN2A, MEN2B and Familial MTC), all characterized by the occurrence of MTC (Jhiang S.M. et al. Oncogene 19, 5590, 2000).
- MEN2A, MEN2B and Familial MTC all characterized by the occurrence of MTC (Jhiang S.M. et al. Oncogene 19, 5590, 2000).
- MEN2A sporadic MTC RET mutations are somatic
- MEN2 patients RET mutations are present at the germline level. These mutations cause constitutive activation of the receptor without modifying its localization at the cell membrane.
- Ret oncoproteins used in this study involve Cys634 (indicated as Ret/MEN2A C634R and Ret/MEN2A C634W ) or Met918 (indicated as Ret/MEN2B M918T ), and represent the most frequently expressed Ret oncoproteins in MEN2A and MEN2B, respectively.
- Cpd 1 The inhibitory effect of Cpd 1 has been demonstrated in murine cells transfected with the RET/MEN2A(C634R) gene ( N iH3T3 MEN2A(c634R) cells) and in the human medullary thyroid carcinoma cell lines TT and MZ- CRC-1, respectively characterized by the expression of Ret/MEN2A(C634W) and Ret/MEN2B(M918T) ( Figures 1, 2). A reduction of the oncoprotein tyrosine-phosphorylation and expression is observed in these cell lines ( Figures 1C and 2A). The inhibition of Ret/MEN2A and Ret/MEN2B receptor autophosphorylation by Cpd 1 is associated with an antiproliferative effect ( Figures IB and 2B).
- N ⁇ H 3T3 MEN2A(C634R) transfectants reverted their transformed phenotype following exposure to Cpdl (Fig. 1A).
- a significant dose-dependent antitumor activity has been observed in nude mice xenografted with the TT tumor: after oral administration of a daily dose of 50- 100 mg/Kg (twice a day), Cpd 1 treatment reached 80% tumor weight inhibition (TWI) without inducing toxicity (Fig. 3).
- TWI tumor weight inhibition
- Fig. 3 The demonstrated pharmacological and biochemical efficacy of Cpd 1 in controlling the proliferation of MTC cells is particularly important considering the aggressiveness of such tumors and the inefficacy of conventional therapies.
- Met the hepatocyte growth factor receptor
- PDGF-R receptor tyrosine kinases
- FGF-R3 receptor tyrosine kinase such as chromosomal traslocations or point mutations produce deregulated, constitutively active, FGF-R3 receptors which have been involved in multiple mieloma and in bladder and cervix carcinomas (Powers CJ. et al. Endocr. Rel. Cancer 7, 165, 2000).
- Cpd 1 The ability of Cpd 1 to down regulate both tyrosine autophosphorylation and expression of FGF-R3 (mutY373C) exogenously expressed in NIH3T3 transfectants is illustrated in Fig. 6B.
- Kit tyrosine kinase is constitutively activated as a consequence of mutations or of its involvement in autocrine loops in different tumors such as small cell lung cancers, gastro-intestinal stromal tumors, seminomas and leukemias (Heinrich M.C. et al. J. Clin. Oncol. 20, 1692, 2002).
- Cpd 1 inhibits the constitutive autophosphorylation and expression of the Kit ( ⁇ 559) mutant exogenously expressed in NIH3T3 cells (Fig. 7B).
- Such inhibition is associated with reversion of the transformed morphologic phenotype of the transfected cells (Fig. 7A).
- Fig. 7A Fig.
- tumor is intended to encompass but is not limited to the abnormal cell proliferation of malignant or non-malignant cells of various tissues and/or organs such as muscle, bone or connective tissue, the skin, brain, lungs, sex organs, the lymphatic or renal systems, mammary or blood cells, liver, the digestive system, pancreas and thyroid or adrenal glands.
- the abnormal cell proliferation can include but is not limited to tumors of the ovary, breast, brain, prostate, colon, liver, lung, ovary, uterus, cervix, pancreas, gastrointestinal tract, head, neck, nasopharynx, skin, bladder, stomach, kidney or testicles, Kaposi's sarcoma, cholangiocarcinoma, choriocarcinoma, neuroblastoma, Wilms' tumor, Hodgkin's disease, melanoma, multiple myeloma, chronic lymphocytic leukemia and acute or chronic granulocytic lymphoma.
- the compounds according to the present invention can be administered alone or in combination with other anti-tumor or anti-cancer agents including but not limited to: adriamycin, daunomycin, methotrexate, vincristin, 6- mercaptopurine, cytosine arabinoside, cyclophosphamide, 5-FU, hexamethylmelamine, carboplatin, cisplatin, idarubycin, paclitaxel, docetaxel, topotecan, irinotecam, gemcitabine, L_PAM, BCNU and VP-16.
- the compounds according to the present invention can also be included in a kit for the treatment of tumors.
- the kit can include additional anti-cancer or anti- tumor agents.
- FIG. 1 Effects of Cpd 1 on NLH3T3 MEN2A(C634R) transfectants expressing exogenous RET/MEN2A(C634R).
- B Antiproliferative effect. N IH3T3 MEN2A(C634R) cells and the parental NIH3T3 cells were treated with increasing concentrations of the drug for 72h and then counted with a Coulter Counter.
- FIG. 1 Effects of Cpdl on human MTC cell lines harboring MEN2- associated RET mutants.
- Whole cell extracts were processed for Western blotting and probed with anti-pTyr and anti-Ret antibodies. As evidenced in anti-pTyr blots, cell treatment with the compound induced a dose-dependent inhibition of tyrosine phosphorylation of Ret receptors in both cell lines.
- a reduced expression of receptor concentrations was observed in cells treated with the highest concentrations of the drug.
- FIG. 3 Antitumor activity of Cpd 1 in nude mice harboring TT medullary thyroid carcinoma xenografts.
- Drug treatment started 25 days after s.c. inoculum of the tumor cells.
- Cpd 1 was delivered per os at 50 or 100 mg/Kg, twice in a day (2qd), for 10 consecutive days (indicated by arrows).
- Control mice received the vehicle.
- the treatment induced a significant dose- dependent inhibition of tumor growth.
- TWI were 60% (P ⁇ 0.005) and 80% (P ⁇ 0.0005) for the 50 mg/Kg and 100 mg/Kg doses, respectively.
- FIG. 4 Inhibition of Met autophosphorylation and expression in human papillary thyroid carcinoma cells (TPC-1) treated with Cpdl.
- TPC- 1 cells were exposed to solvent (-) or the indicated concentrations of Cpd 1 for 72h. Equal amounts of protein were used for immunoprecipitation (IP) with anti-Met antibody or for the preparation of whole cell lysates (WCL). Immunoprecipitated proteins and WCLs were separated by SDS-PAGE, transferred to nitrocellulose membranes, and subjected to Western blotting with anti-pTyr or anti-Met antibodies.
- FIG. 5 Inhibition of PDGF-R autophosphorylation and expression in whole cells by Cpd 1.
- Figure 7 Effects of Cpdl on cell lines expressing constitutively activated forms of Kit.
- A) Reversion of the transformed morphologic phenotype of NIH3T3 transfectants expressing exogenous mutated KIT ( ⁇ 559). Cells were treated with 20 ⁇ M Cpdl and photographed 24h later under a phase-contrast microscope (original magnification X 100).
- the following human medullary thyroid carcinoma (MTC) cell lines were used in this study.
- the TT cell line derived from a MEN2A-associated MTC characterized by expression of the RET oncogene carrying the mutation C634W.
- the MZ-CRC-1 cell line derived from MEN2B-associated MTC characterized by expression of the RET oncogene carrying the mutation M918T.
- TT cells were cultivated in Ham's F12 medium (BioWhittaker, Verviers, Belgium) supplemented with 15% fetal calf serum (FCS) (Life Technologies, Inc., Gaithersburg, MD) whereas MZ-CRC-1 cells were grown in Dulbecco's modified Eagle's medium (DMEM) (BioWhittaker) supplemented with 10% FCS.
- FCS fetal calf serum
- DMEM Dulbecco's modified Eagle's medium
- the human papillary thyroid carcinoma cell line TPC-1 which was used as a model of Met overexpression, was routinely cultivated in DMEM with 10% FCS.
- N592 cells derived from a human SCLC, were characterized by Kit activation through autocrine stimulation by the SCF ligand. N592 cells were cultured in RPMI 1640 supplemented with 10% FCS.
- the mouse SWISS3T3 and NIH3T3 fibroblasts were cultured in DMEM with 10% calf serum (Colorado Serum Company, Denver, CO).
- NIH3T3 cells transfected with different oncogenes were used.
- NIH3T3 MEN2A transfectants express the short isoform of the RET-MEN2A (C634R) oncogene;
- NIH3T3 KITA559 cells express KIT carrying the activating mutation ⁇ 559 found in GISTs;
- NIH 3T3 FGFR3(Y373C) express the FGF-R3 gene carrying the activating mutation Y373C found in a human multiple myeloma cell line.
- 2N5A cells are NIH3T3 cells transformed by the COL1A1/PDGFB rearrangement generating autocrine stimulation of PDGF-R. All NIH3T3 transfectants were maintained in DMEM plus 5% calf serum in a 10% C0 2 atmosphere. Antiproliferative assays
- NIH3T3 and NIH3T3 MEN2A cells were trypsinized after 3 days (NIH3T3 and NIH3T3 MEN2A cells) or 7 days (MTC cells) of treatment with Cpdl and counted by a Coulter Counter (Coulter Electronics, Luton U.K.). The concentrations able to inhibit cell proliferation by 50% (IC 50 ) were calculated from the dose-response curves. Each experiment was performed in duplicate Antibodies The following polyclonal antibodies were used: anti-Ret recognizing a
- COOH-terminal sequence (aa 1000-1014) common to the two Ret isoforms (Borrello M. G., et al., Mol. Cell Biol. 16, 2151, 1996); anti-cKit, anti-Met and anti-FGF-R3 from Santa Cruz Biotechnology (Santa Cruz, CA); anti-actin from Sigma (St. Louis, MO); anti-PDGF-R ⁇ / ⁇ from Upstate Biotechnology (Lake Placid, NY); anti phospho-cKit (Tyr 719) from Cell Signaling Technology (Beverly, MA).
- the mouse monoclonal anti-phosphotyrosine (anti-pTyr) 4G10 and anti-FGF-Rl antibodies were from Upstate Biotechnology.
- Protein concentration was determined in appropriately diluted aliquots by the bicinchionic acid (BCA) method (Pierce, Rockford, IL), then samples were adjusted to a final concentration of 10%» glycerol, 5% ⁇ -mercaptoethanol, 0.001% bromophenol blue.
- BCA bicinchionic acid
- cells were treated with Cpdl or solvent for the indicated times.
- Cell monolayers were rinsed twice with cold phosphate-buffered saline plus 0.1 mM sodium orthovanadate and then left for 20 min on ice in lysis buffer (50mM HEPES pH7.6, 150mM NaCl, 10 % glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 100 mM NaF, 10 mM sodium pyrophosphate, 10 ⁇ g/ml antipain, 20 ⁇ g/ml chymostatin, 10 ⁇ g/ml E64, 1 mg/ml pefabloc SC).
- lysis buffer 50mM HEPES pH7.6, 150mM NaCl, 10 % glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 100 mM NaF, 10 mM sodium pyr
- Cells were then collected, aspirated through a 22-gauge needle and centrifuged at lOOOOg, for 20 min, at 4 °C. Protein concentration was determined by the BCA reagent (Pierce). Cell extracts were incubated with protein A-agarose and the indicated antibody for 2 hr at 4°C under rotation. After washing 3 times with 20mM HEPES pH 7.6, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100, the immunoprecipitates were eluted with complete sample buffer.
- the E configuration of the esocyclic double bond in position 2 was determined by means of ID NOE NMR experiments.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03765081A EP1534271B1 (en) | 2002-07-23 | 2003-07-22 | Antitumor compound and therapeutic uses thereof |
CA002493202A CA2493202A1 (en) | 2002-07-23 | 2003-07-22 | Antitumor compound and therapeutic uses thereof |
MXPA05000781A MXPA05000781A (en) | 2002-07-23 | 2003-07-22 | Antitumor compound and therapeutic uses thereof. |
US10/522,081 US20060258731A1 (en) | 2002-07-23 | 2003-07-22 | Antitumor compound and therapeutic uses thereof |
JP2004522542A JP2005537277A (en) | 2002-07-23 | 2003-07-22 | Antitumor compounds and their therapeutic use |
DE60307856T DE60307856T2 (en) | 2002-07-23 | 2003-07-22 | ANTITUMORIC CONNECTION AND ITS THERAPEUTIC USES |
AU2003251437A AU2003251437A1 (en) | 2002-07-23 | 2003-07-22 | Antitumor compound and therapeutic uses thereof |
US12/313,033 US20090130229A1 (en) | 2002-07-23 | 2008-11-13 | Antitumor uses of compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2002MI001620A ITMI20021620A1 (en) | 2002-07-23 | 2002-07-23 | ANTI-TUMORAL ACTIVITY COMPOUND |
ITMI02A001620 | 2002-07-23 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/313,033 Continuation US20090130229A1 (en) | 2002-07-23 | 2008-11-13 | Antitumor uses of compound |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004009083A1 true WO2004009083A1 (en) | 2004-01-29 |
WO2004009083A8 WO2004009083A8 (en) | 2005-02-03 |
Family
ID=30130912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/007963 WO2004009083A1 (en) | 2002-07-23 | 2003-07-22 | Antitumor compound and therapeutic uses thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US20060258731A1 (en) |
EP (1) | EP1534271B1 (en) |
JP (1) | JP2005537277A (en) |
CN (1) | CN1668298A (en) |
AT (1) | ATE337001T1 (en) |
AU (1) | AU2003251437A1 (en) |
CA (1) | CA2493202A1 (en) |
DE (1) | DE60307856T2 (en) |
ES (1) | ES2271649T3 (en) |
IT (1) | ITMI20021620A1 (en) |
MX (1) | MXPA05000781A (en) |
WO (1) | WO2004009083A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005068424A1 (en) * | 2004-01-20 | 2005-07-28 | Cell Therapeutics Europe S.R.L. | Indolinone derivatives as receptor tyrosine kinase ihibitors |
EP1883403A2 (en) * | 2005-04-29 | 2008-02-06 | The Ohio State University Research Foundation | Keratinocyte growth factor receptor - tyrosine specific inhibitors for the prevention of cancer metastatis |
WO2008029123A1 (en) * | 2006-09-07 | 2008-03-13 | Astrazeneca Ab | Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103965200B (en) | 2008-09-22 | 2016-06-08 | 阵列生物制药公司 | As imidazo [1,2-B] pyridazine compound of the replacement of TRK kinase inhibitor |
AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
SG11201703962XA (en) | 2014-11-16 | 2017-06-29 | Array Biopharma Inc | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
AU2016291676B2 (en) | 2015-07-16 | 2020-04-30 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
RU2744852C2 (en) | 2015-10-26 | 2021-03-16 | Локсо Онколоджи, Инк. | Point mutations in trk inhibitor-resistant malignant tumors and related methods |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
KR102400423B1 (en) | 2016-04-04 | 2022-05-19 | 록쏘 온콜로지, 인코포레이티드 | (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidine-3- Liquid formulation of yl)-3-hydroxypyrrolidine-1-carboxamide |
CN109310694A (en) | 2016-04-04 | 2019-02-05 | 洛克索肿瘤学股份有限公司 | The method for treating Paediatric cancer |
LT3800189T (en) | 2016-05-18 | 2023-10-10 | Loxo Oncology, Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JP6888101B2 (en) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrazolo [1,5-a] pyrazine compounds as RET kinase inhibitors |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
TW201938169A (en) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[3,4-d]pyrimidine compounds as RET kinase inhibitors |
CN111971286B (en) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors |
US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
CN112996794A (en) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | Fused heterocyclic compounds as RET kinase inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6130238A (en) * | 1997-06-20 | 2000-10-10 | Sugen, Inc. | 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors |
US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
US6147106A (en) * | 1997-08-20 | 2000-11-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
US6268391B1 (en) * | 1997-08-06 | 2001-07-31 | Glaxo Wellcome Inc. | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5502072A (en) * | 1993-11-26 | 1996-03-26 | Pfizer Inc. | Substituted oxindoles |
ES2290117T3 (en) * | 2000-02-15 | 2008-02-16 | Sugen, Inc. | PROTEIN QUINASE 2-INDOLIN INHIBITORS REPLACED WITH PIRROL. |
-
2002
- 2002-07-23 IT IT2002MI001620A patent/ITMI20021620A1/en unknown
-
2003
- 2003-07-22 AT AT03765081T patent/ATE337001T1/en not_active IP Right Cessation
- 2003-07-22 WO PCT/EP2003/007963 patent/WO2004009083A1/en active IP Right Grant
- 2003-07-22 CN CNA038173352A patent/CN1668298A/en active Pending
- 2003-07-22 AU AU2003251437A patent/AU2003251437A1/en not_active Abandoned
- 2003-07-22 ES ES03765081T patent/ES2271649T3/en not_active Expired - Lifetime
- 2003-07-22 EP EP03765081A patent/EP1534271B1/en not_active Expired - Lifetime
- 2003-07-22 MX MXPA05000781A patent/MXPA05000781A/en active IP Right Grant
- 2003-07-22 CA CA002493202A patent/CA2493202A1/en not_active Abandoned
- 2003-07-22 JP JP2004522542A patent/JP2005537277A/en active Pending
- 2003-07-22 US US10/522,081 patent/US20060258731A1/en not_active Abandoned
- 2003-07-22 DE DE60307856T patent/DE60307856T2/en not_active Expired - Lifetime
-
2008
- 2008-11-13 US US12/313,033 patent/US20090130229A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6130238A (en) * | 1997-06-20 | 2000-10-10 | Sugen, Inc. | 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors |
US6268391B1 (en) * | 1997-08-06 | 2001-07-31 | Glaxo Wellcome Inc. | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases |
US6147106A (en) * | 1997-08-20 | 2000-11-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
Non-Patent Citations (3)
Title |
---|
CINZIA LANZI AND ALL.: "Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative", INT.J.CANCER, vol. 85, 2000, pages 384 - 390, XP002257784 * |
SARASIN A ET AL: "Mechanisms of mutagenesis in mammalian cells. Application to human thyroid tumours", COMPTES RENDUS DES SEANCES DE L'ACADEMIE DES SCIENCES. SERIE III: SCIENCES DE LA VIE, ELSEVIER, AMSTERDAM, NL, vol. 322, no. 2-3, February 1999 (1999-02-01), pages 143 - 149, XP004270260, ISSN: 0764-4469 * |
SUAREZ H G: "Molecular basis of epithelial thyroid tumorigenesis", COMPTES RENDUS DES SEANCES DE L'ACADEMIE DES SCIENCES. SERIE III: SCIENCES DE LA VIE, ELSEVIER, AMSTERDAM, NL, vol. 323, no. 6, June 2000 (2000-06-01), pages 519 - 528, XP004330637, ISSN: 0764-4469 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005068424A1 (en) * | 2004-01-20 | 2005-07-28 | Cell Therapeutics Europe S.R.L. | Indolinone derivatives as receptor tyrosine kinase ihibitors |
EP1883403A2 (en) * | 2005-04-29 | 2008-02-06 | The Ohio State University Research Foundation | Keratinocyte growth factor receptor - tyrosine specific inhibitors for the prevention of cancer metastatis |
EP1883403A4 (en) * | 2005-04-29 | 2011-02-16 | Univ Ohio State Res Found | Keratinocyte growth factor receptor - tyrosine specific inhibitors for the prevention of cancer metastatis |
WO2008029123A1 (en) * | 2006-09-07 | 2008-03-13 | Astrazeneca Ab | Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase |
Also Published As
Publication number | Publication date |
---|---|
CA2493202A1 (en) | 2004-01-29 |
ES2271649T3 (en) | 2007-04-16 |
CN1668298A (en) | 2005-09-14 |
DE60307856T2 (en) | 2007-04-12 |
US20060258731A1 (en) | 2006-11-16 |
JP2005537277A (en) | 2005-12-08 |
EP1534271A1 (en) | 2005-06-01 |
WO2004009083A8 (en) | 2005-02-03 |
AU2003251437A8 (en) | 2004-02-09 |
ATE337001T1 (en) | 2006-09-15 |
ITMI20021620A1 (en) | 2004-01-23 |
MXPA05000781A (en) | 2005-09-21 |
EP1534271B1 (en) | 2006-08-23 |
DE60307856D1 (en) | 2006-10-05 |
AU2003251437A1 (en) | 2004-02-09 |
US20090130229A1 (en) | 2009-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090130229A1 (en) | Antitumor uses of compound | |
EP3009428B1 (en) | Diamino heterocyclic carboxamide compound | |
JP2011518174A (en) | Compounds and methods for treating diseases associated with estrogen receptors | |
US20210154198A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
EA028452B1 (en) | Treatment of breast cancer | |
CA3074418C (en) | Exon 18 and/or exon 21 mutant egfr selective inhibitor | |
KR20160013164A (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
US20180250261A1 (en) | Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor | |
KR20160110952A (en) | Novel methods for treating cancer | |
KR20100051837A (en) | Treatment of pediatric tumors | |
CN104271129A (en) | Methods of treating cancer using aurora kinase inhibitors | |
KR20170040338A (en) | Treatment of androgen deprivation therapy associated symptoms | |
KR100847413B1 (en) | Pharmaceutical Combinations Based on Pyridoindolone Derivatives and Anticancer Agents | |
JP2021527119A (en) | Salt form | |
TW202227450A (en) | Brain-migrating tumor therapeutic agent containing fused pyrimidine compound as active ingredient | |
WO2023198078A1 (en) | Polycyclic compounds as kras g12d inhibitors | |
KR20230110296A (en) | Kinase Inhibitor Combinations for Cancer Treatment | |
CN113164438A (en) | Novel combination regimen for treating chemotherapy-refractory cancer | |
EA046190B1 (en) | NEW COMBINED SOLUTION FOR THE TREATMENT OF CANCER RESISTANT TO CHEMOTHERAPY | |
KR20200061823A (en) | Use of pyrimidinone derivatives having apoptosis of brain cancer stem cells | |
KR20200061822A (en) | Use of pyrimidinedione derivatives having apoptosis of brain cancer stem cells | |
TW201143766A (en) | Antitumor agent containing indole compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/000781 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2493202 Country of ref document: CA Ref document number: 2004522542 Country of ref document: JP Ref document number: 20038173352 Country of ref document: CN |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 05/2004 UNDER (71) THE NAME SHOULD READ "ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI" |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003765081 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003765081 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006258731 Country of ref document: US Ref document number: 10522081 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003765081 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10522081 Country of ref document: US |